Clin2
NCT06568367Possibly a fitRecruiting

Solriamfetol for shift work disorder (SUSTAIN trial)

Excessive SleepinessShift-work Disorder

Treatments studied

Part of Brain & nervous system, Mental health clinical trials.

This study tests a medication called Solriamfetol (Sunosi) to see if it helps people with shift work disorder stay awake and alert during their shifts. It is a Phase 3 trial, which means it is being studied in a larger group to confirm how well it works and check for side effects.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
520 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You must have been diagnosed with shift work disorder (trouble sleeping or staying awake due to your work schedule).
  • You cannot have taken the study drug Solriamfetol (also called Sunosi) before.
  • You must be between 18 and 65 years old.
  • You must be able to follow the study procedures and give your written permission to participate.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05424406Recruiting
Studying sleep timing changes in people with night-shift disorder

This study looks at how changes in your body clock (circadian timing) relate to “shift work disorder” in people who work night shifts. It may help researchers understand what drives symptoms and how to better target treatment.

Novi, Michigan
NCT07717892Recruiting· Phase 3
Solriamfetol for teens with ADHD

This study tests a new medicine, solriamfetol, to see if it helps teenagers with ADHD. The medicine is taken as a tablet and may improve focus and reduce symptoms.

Dothan, Alabama
NCT07717879Recruiting· Phase 3
Testing solriamfetol for children with ADHD

This trial tests whether a medication called solriamfetol can safely help children with ADHD. If your child is between 6 and 12 years old and has ADHD, this study may be an option.

Dothan, Alabama
NCT07773883Enrolling by invitation· Phase 3
Long-term safety of solriamfetol for ADHD in children and teens

This study checks the long-term safety of the drug solriamfetol for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents who have already completed an earlier study of this medication.

Dothan, Alabama
NCT06843590Recruiting· Phase 2
Study of ALKS 2680 for Idiopathic Hypersomnia

This trial tests a new medicine called ALKS 2680 for people with Idiopathic Hypersomnia (a condition that causes extreme sleepiness without a clear cause). The goal is to see if it is safe and effective at helping you stay awake during the day.

Cullman, Alabama
NCT06590662Not yet recruiting· Phase 2
Solriamfetol for idiopathic hypersomnia

This trial tests a medication, solriamfetol, to see if it helps people with idiopathic hypersomnia stay awake during the day. It may be an option if you have trouble staying awake despite getting enough sleep at night.

Montpellier

Hear when a new Shift-work Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.